The Fort Worth Press - Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

USD -
AED 3.672498
AFN 64.494403
ALL 82.253977
AMD 360.50962
ANG 1.790403
AOA 917.502481
ARS 1552.246096
AUD 1.485112
AWG 1.8
AZN 1.702078
BAM 1.779545
BBD 2.01413
BDT 124.905034
BGN 1.77347
BHD 0.377203
BIF 3005
BMD 1
BND 1.288858
BOB 11.66537
BRL 5.777898
BSD 1.000059
BTN 93.425596
BWP 13.998644
BYN 3.001178
BYR 19600
BZD 2.011401
CAD 1.429395
CDF 2293.999606
CHF 0.839925
CLF 0.025261
CLP 994.199792
CNY 6.66615
CNH 6.66639
COP 3309.14
CRC 445.481718
CUC 1
CUP 24.000873
CVE 100.450399
CZK 22.134398
DJF 177.720413
DKK 6.79105
DOP 60.449654
DZD 137.026986
EGP 53.720699
ERN 15
ETB 164.140883
EUR 0.90863
FJD 2.297767
FKP 0.758367
GBP 0.757025
GEL 2.595028
GGP 0.758367
GHS 11.740303
GIP 0.758367
GMD 73.999853
GNF 8859.999559
GTQ 7.643069
GYD 209.144677
HKD 7.846185
HNL 26.886001
HRK 6.831965
HTG 131.024035
HUF 333.23026
IDR 18260
ILS 3.254645
IMP 0.758367
INR 93.44335
IQD 1516.079284
IRR 1929053.501903
ISK 124.288047
JEP 0.758367
JMD 158.919789
JOD 0.709015
JPY 159.346977
KES 130.040331
KGS 87.448989
KHR 4074.999997
KMF 448.000209
KPW 900.00035
KRW 1334.749919
KWD 0.31166
KYD 0.833458
KZT 444.016797
LAK 22537.499188
LBP 89550.000289
LKR 332.782835
LRD 168.750107
LSL 16.919297
LTL 2.95274
LVL 0.60489
LYD 6.462884
MAD 9.981438
MDL 18.311519
MGA 4549.44565
MKD 55.931125
MMK 2099.8229
MNT 3605.49036
MOP 8.082545
MRU 40.524838
MUR 47.859786
MVR 15.409659
MWK 1734.212921
MXN 18.428599
MYR 4.093697
MZN 63.902086
NAD 16.918528
NGN 1348.259779
NIO 36.80602
NOK 9.621275
NPR 149.481136
NZD 1.82025
OMR 0.384502
PAB 1.000032
PEN 3.415635
PGK 4.499381
PHP 63.619604
PKR 276.505202
PLN 3.99989
PYG 6230.864068
QAR 3.64562
RON 4.859598
RSD 106.886981
RUB 82.05005
RWF 1480.116648
SAR 3.756442
SBD 8.098361
SCR 13.913581
SDG 601.497935
SEK 10.1178
SGD 1.288285
SHP 0.758581
SLE 23.049753
SLL 20969.503664
SOS 571.501363
SRD 37.438005
STD 20697.981008
STN 22.292284
SVC 8.750364
SYP 13002.000337
SZL 16.918877
THB 33.789739
TJS 9.216015
TMT 3.51
TND 3.026264
TOP 2.40776
TRY 50.415055
TTD 6.771395
TWD 32.928797
TZS 2650.002987
UAH 45.33545
UGX 4149.985442
UYU 40.627659
UZS 12019.053598
VES 915.501901
VND 25712.5
VUV 120.845902
WST 2.802705
XAF 596.022501
XAG 0.021143
XAU 0.000259759826
XCD 2.70255
XCG 1.802383
XDR 0.707052
XOF 596.022501
XPF 108.509428
YER 236.503848
ZAR 16.935602
ZMK 9001.196993
ZMW 20.486504
ZWL 321.999592
SSP 5946.953244
MXV 2.067401
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

Canalevia®-CA1, Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea in dogs, has received extension of conditional approval by FDA

Text size:

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today issued a reminder that company personnel are attending the Pet Connect conference, taking place December 3-5, 2024 in Los Angeles, and are available for partnership discussions at the event. Jaguar is seeking a partner to fund and execute the development and commercialization of NP300, the company's prescription drug candidate for the treatment of general, non-infectious diarrhea in dogs, in exchange for commercial rights to the product in the U.S.

NP300 is a novel antisecretory drug with a similar mechanism of action to Canalevia®-CA1 (crofelemer delayed-release tablets), the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. NP300 has demonstrated safety in dogs and is sustainably derived from the Croton lechleri tree, the same source as that for crofelemer.

"We look forward to evaluating NP300 for treatment of general, non-infectious diarrhea in dogs, and to identifying a partner organization to fund and execute development and commercialization of the product," said David Sesin, PhD, Jaguar's Chief Manufacturing Officer. "We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet need for a product to treat general, non-infectious diarrhea in dogs as well. We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs. We are attending the Pet Connect conference with the goal of speaking with potential partners about NP300."

Diarrhea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drug to treat canine diarrhea. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of U.S. households owning a dog in 2024. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of control in urban settings where owners don't have easy access to outdoor facilities is a significant problem for families with dogs.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Important Safety Information About Canalevia-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that company personnel will attend the December 3-5, 2024 Pet Connect conference, and Jaguar's expectation that it may identify a partner organization to fund and execute development and commercialization of NP300. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.

Contact:

[email protected]

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

A.Williams--TFWP